Off-label use of canakinumab in pediatric rheumatology and rare diseases

Since the first success of interleukin-1 blockade in cryopyrin-associated periodic syndrome, the use of interleukin-1 inhibitors has expanded to other disorders, including off-label indications. In particular, canakinumab has been employed in an off-label fashion in several diseases such as rare mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Giudice, Emanuela, Sota, Jurgen, Orlando, Francesca, Picciano, Ludovica, Cimaz, Rolando, Cantarini, Luca, Mauro, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622922/
https://www.ncbi.nlm.nih.gov/pubmed/36330067
http://dx.doi.org/10.3389/fmed.2022.998281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622922/
https://www.ncbi.nlm.nih.gov/pubmed/36330067
http://dx.doi.org/10.3389/fmed.2022.998281

Ejemplares similares